Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04202341 · ClinicalTrials.gov registry record
Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
A clinical trial of Generalized Myasthenia Gravis, sponsored by Alexion Pharmaceuticals.
- Recruiting
- Registry status
- 500
- Enrollment target
- 20
- Study locations
NCT04202341: Recruiting study of Generalized Myasthenia Gravis, sponsored by Alexion Pharmaceuticals.
NCT04202341 is a study of Generalized Myasthenia Gravis that is actively recruiting participants, run by Alexion Pharmaceuticals. The registered enrollment target is 500 participants, above the 112-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (346% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04202341, a study of Generalized Myasthenia Gravis, is actively recruiting participants, sponsored by Alexion Pharmaceuticals.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 20
- Study locations
Study Summary
Long-term, multicenter, multinational, observational, registry of patients with gMG that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT) such as eculizumab (Soliris®) and ravulizumab (Ultomiris®).
Primary Outcome
The MG-ADL is an eight-item patient-reported outcome measure assessing MG symptoms and functional activities related to activities of daily living.48 Each of the items is scored from 0 (normal) to 3 (most severe), providing a total MG-ADL score ranging from 0 to 24, where higher scores indicate greater severity of symptoms.
Conditions Studied
Study Locations (20)
California
- Clinical Trial Site - Fresno
- Clinical Trial Site - Orange
- Clinical Trial Site - Rancho Mirage
- Clinical Trial Site - Sylmar
Florida
- Clinical Trial Site - Clearwater
- Clincal Trial Site - Gainesville
- Clinical Trial Site - Jacksonville
- Clinical Trial Site - Tampa
Colorado
- Clinical Trial Site - Colorado Springs
- Clinical Trial Site - Fort Collins
Alabama
- Clinical Trial Site - Birmingham
Arizona
- Clinical Trial Site - Scottsdale
Connecticut
- Clinical Trial Site - New Haven
District of Columbia
- Clinical Trial Site - Washington D.C.
Georgia
- Clinical Trial Site - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2019-12-02 |
| Est. Completion | 2029-10-01 |
What NCT04202341 shows while recruiting
NCT04202341 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 112-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (346% higher).
The record links to 1 condition, with Generalized Myasthenia Gravis appearing as the primary indexed condition, and to 0 interventions.
NCT04202341 names 20 study sites across 13 states, led by California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT04202341 about?
NCT04202341 is a clinical study titled "Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)". Long-term, multicenter, multinational, observational, registry of patients with gMG that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT) such as eculizumab (Soliris®) and ravulizumab (Ultomiris®).
What is the current status of trial NCT04202341?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2019-12-02. Estimated completion is 2029-10-01.
What conditions does trial NCT04202341 study?
This clinical trial studies the following conditions: Generalized Myasthenia Gravis.
Who is sponsoring clinical trial NCT04202341?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04202341 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Generalized Myasthenia Gravis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04202341's enrollment target sits among peer trials
500 1st of 26 higher than 26 of 26 other Generalized Myasthenia Gravis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Generalized Myasthenia Gravis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
RECRUITING · Phase 3
-
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
RECRUITING · Phase 3
-
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
RECRUITING · Phase 2
-
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis
RECRUITING · Phase 2
-
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
RECRUITING
-
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI